Pipeline Insight: Osteoporosis - Intermittent dosing drives market growth

Questions: Discounts, Updates etc.

Price: $11,400.00

Publication Date: 2007-03-30

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

The long-standing unmet need of the osteoporosis market has been for improved adherence to treatment. Two pipeline products, Amgen's Denosumab and Novartis' Aclasta (zoledronate), have answered this demand with intermittent dosing schedules and consequently are expected to generate blockbuster revenues. This will rejuvenate the market which is otherwise stalling under multiple patent expiries.


Scope

  • Analysis of patient potential, unmet needs and clinical trial design in osteoporosis
  • Overview of drugs in late- and early-stage clinical development; with analysis of key companies involved in the R&D pipeline
  • Detailed profiles of key compounds in development for use in osteoporosis, with forecasts of drug revenues to 2016
  • Review of the key strategies adopted by current market players


    • Report Highlights
    Despite the genericization of the market leader Fosamax in the US and Japan and patent expiries on other key brands, pipeline products are still viable. Datamonitor expects pipeline products to swell the total market value 59.6% between 2007 and 2016 to $11.1 billion.

    Products that offer intermittent dosing schedules are highly desirable in the osteoporosis market and can generate blockbuster revenues. Such therapies answer the demand from patients and physicians for more convenient delivery mechanisms that increase compliance and ultimately improve treatment outcome.

    Although bisphosphonates are the mainstay of osteoporosis treatment, there is potential for new and innovative products to gain market share. Those that suit niche populations, such as Amgen's ED-71 which finds favor as a vitamin D analogue in Japan, will be able to fight generic competition.


    Reasons to Purchase

  • Understand clinical and environmental unmet needs in the osteoporosis market based on key opinion leader comments
  • Benchmark key late-stage pipeline products against the current market leader and class comparator
  • Assess the global (US, Japan, five major EU) sales forecasts of key late-stage pipeline drugs; and examine their clinical and commercial potential

    • Table of Contents

    Other users found this report page using the following search terms: osteoporosis bone menopause osteoporosis pipeline denosumab market atc datamonitor patent class pth share

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.